Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 3
1995 5
1996 6
1997 5
1998 3
1999 1
2000 7
2001 4
2002 4
2003 4
2004 3
2005 4
2006 5
2007 3
2008 4
2009 3
2010 4
2011 4
2012 1
2013 4
2014 4
2015 6
2016 3
2017 13
2018 12
2019 11
2020 11
2021 10
2022 12
2023 9
2024 7
2025 2
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

166 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, Invernizzi P, Jones D, Kruger FC, Lawitz E, Mayo MJ, Shiffman ML, Swain MG, Valera JM, Vargas V, Vierling JM, Villamil A, Addy C, Dietrich J, Germain JM, Mazain S, Rafailovic D, Taddé B, Miller B, Shu J, Zein CO, Schattenberg JM; ELATIVE Study Investigators’ Group; ELATIVE Study Investigators' Group. Kowdley KV, et al. Among authors: swain mg. N Engl J Med. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13. N Engl J Med. 2024. PMID: 37962077 Clinical Trial.
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.
Hirschfield GM, Shiffman ML, Gulamhusein A, Kowdley KV, Vierling JM, Levy C, Kremer AE, Zigmond E, Andreone P, Gordon SC, Bowlus CL, Lawitz EJ, Aspinall RJ, Pratt DS, Raikhelson K, Gonzalez-Huezo MS, Heneghan MA, Jeong SH, Ladrón de Guevara AL, Mayo MJ, Dalekos GN, Drenth JPH, Janczewska E, Leggett BA, Nevens F, Vargas V, Zuckerman E, Corpechot C, Fassio E, Hinrichsen H, Invernizzi P, Trivedi PJ, Forman L, Jones DEJ, Ryder SD, Swain MG, Steinberg A, Boudes PF, Choi YJ, McWherter CA; ENHANCE Study Group*. Hirschfield GM, et al. Among authors: swain mg. Hepatology. 2023 Aug 1;78(2):397-415. doi: 10.1097/HEP.0000000000000395. Epub 2023 Apr 6. Hepatology. 2023. PMID: 37386786 Free PMC article. Clinical Trial.
Liver-brain inflammation axis.
D'Mello C, Swain MG. D'Mello C, et al. Among authors: swain mg. Am J Physiol Gastrointest Liver Physiol. 2011 Nov;301(5):G749-61. doi: 10.1152/ajpgi.00184.2011. Epub 2011 Aug 25. Am J Physiol Gastrointest Liver Physiol. 2011. PMID: 21868631 Free article. Review.
Anti-TNF-induced autoimmune hepatitis.
Borman MA, Urbanski S, Swain MG. Borman MA, et al. Among authors: swain mg. J Hepatol. 2014 Jul;61(1):169-70. doi: 10.1016/j.jhep.2014.01.032. Epub 2014 Mar 15. J Hepatol. 2014. PMID: 24636834 Free article. No abstract available.
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis.
Bowlus CL, Galambos MR, Aspinall RJ, Hirschfield GM, Jones DEJ, Dörffel Y, Gordon SC, Harrison SA, Kremer AE, Mayo MJ, Thuluvath PJ, Levy C, Swain MG, Neff GW, Sheridan DA, Stanca CM, Berg CP, Goel A, Shiffman ML, Vierling JM, Boudes P, Steinberg A, Choi YJ, McWherter CA. Bowlus CL, et al. Among authors: swain mg. J Hepatol. 2022 Aug;77(2):353-364. doi: 10.1016/j.jhep.2022.02.033. Epub 2022 Mar 30. J Hepatol. 2022. PMID: 35367282 Free article. Clinical Trial.
Fatigue in chronic disease.
Swain MG. Swain MG. Clin Sci (Lond). 2000 Jul;99(1):1-8. Clin Sci (Lond). 2000. PMID: 10887052 Review.
Assessment of fatigue and its impact in chronic liver disease.
Younossi ZM, Kremer AE, Swain MG, Jones D, Bowlus C, Trauner M, Henry L, Gerber L. Younossi ZM, et al. Among authors: swain mg. J Hepatol. 2024 Oct;81(4):726-742. doi: 10.1016/j.jhep.2024.04.008. Epub 2024 Apr 24. J Hepatol. 2024. PMID: 38670320 Review.
Role of Peripheral Inflammation in Hepatic Encephalopathy.
Azhari H, Swain MG. Azhari H, et al. Among authors: swain mg. J Clin Exp Hepatol. 2018 Sep;8(3):281-285. doi: 10.1016/j.jceh.2018.06.008. Epub 2018 Jun 25. J Clin Exp Hepatol. 2018. PMID: 30302045 Free PMC article. Review.
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
Mayo MJ, Vierling JM, Bowlus CL, Levy C, Hirschfield GM, Neff GW, Galambos MR, Gordon SC, Borg BB, Harrison SA, Thuluvath PJ, Goel A, Shiffman ML, Swain MG, Jones DEJ, Trivedi P, Kremer AE, Aspinall RJ, Sheridan DA, Dörffel Y, Yang K, Choi YJ, McWherter CA. Mayo MJ, et al. Among authors: swain mg. Aliment Pharmacol Ther. 2024 Jan;59(2):186-200. doi: 10.1111/apt.17755. Epub 2023 Oct 30. Aliment Pharmacol Ther. 2024. PMID: 37904314
166 results